Infliximab administered with shortened infusion times in a specialized IBD infusion unit: A prospective cohort study

Journal of Crohn's and Colitis

Volumn 4, Issue 3, 2010, Pages 329-333

  Van Assche, Gert ^a   Vermeire, Séverine ^a   Noman, Maja ^a   Amant, Christine ^a   Weyts, Ellen ^a   Vleminckx, Anita ^a   Vermeyen, Marie Josée ^a   Rutgeerts, Paul ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Crohn's disease; Inflammatory bowel disease; Infliximab; Infusion reactions; Medical therapy; Ulcerative colitis

Indexed keywords

INFLIXIMAB;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; FEMALE; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR;

EID: 77955281761     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2009.12.012     Document Type: Article

References (10)

1. Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present DH., Braakman T., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997, 337:1029-1035.
2. Present D.H., Rutgeerts P., Targan S., Hanauer SB., Mayer L., van Hogezand R.A., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999, 340:1398-1405.
3. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel JF., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
4. Sands B.E., Anderson F.H., Bernstein C.N., Chey WY., Feagan BG., Fedorak RN., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med Feb 26 2004, 350(9):876-885.
5. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353(23):2462-2476.
6. Fidder H., Schnitzler F., Ferrante M., Noman M., Katsanos K., Segaert S., et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009, 58:501-508.
7. Remicade, SPC. http://emc.medicines.org.uk/document.aspx?documentId=3236. Read on Oct 26, 2009.
8. Clare D.F., Alexander F.C., Mike S., Dan G., Allan F., Lisa W., et al. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2009, 21:71-75.
9. Buch M.H., Bryer D., Lindsay S., Rees-Evans B., Fairclough A., Emery P. Shortening infusion times for infliximab administration. Rheumatology 2006, 45:485-486.
10. van Vollenhoven R.F., Gullström E., Klareskog L. Feasibility of 1 hour infliximab infusions. Ann Rheum Dis 2005, 64:654.